[{"address1": "Gooimeer 2-35", "city": "Naarden", "zip": "1411 DC", "country": "Netherlands", "phone": "31 35 206 2971", "website": "https://www.newamsterdampharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.", "fullTimeEmployees": 68, "companyOfficers": [{"maxAge": 1, "name": "Mr. Mayur Amrat Somaiya", "age": 50, "title": "Chief Financial Officer", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 841238, "exercisedValue": 0, "unexercisedValue": 3954412}, {"maxAge": 1, "name": "Mr. Douglas F. Kling", "age": 51, "title": "Chief Operating Officer", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 913742, "exercisedValue": 0, "unexercisedValue": 17441960}, {"maxAge": 1, "name": "Ms. Juliette  Audet M.B.A., M.Sc.", "age": 37, "title": "Chief Strategy & Business Officer", "yearBorn": 1987, "fiscalYear": 2024, "totalPay": 653039, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Louise  Kooij", "age": 48, "title": "Chief Accounting Officer", "yearBorn": 1976, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew  Philippe", "title": "Executive VP &Head of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bob  Rambo", "title": "Executive Vice President of Marketing", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Maryellen  McQuade", "title": "Chief People Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Marc  Ditmarsch M.D.", "age": 57, "title": "Chief Development Officer", "yearBorn": 1967, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sheng  Cui Ph.D.", "title": "Chief Manufacturing Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Annie  Neild", "title": "Executive VP & Head of Global Regulatory Affairs", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 24.44, "open": 24.61, "dayLow": 24.35, "dayHigh": 25.65, "regularMarketPreviousClose": 24.44, "regularMarketOpen": 24.61, "regularMarketDayLow": 24.35, "regularMarketDayHigh": 25.65, "payoutRatio": 0.0, "beta": -0.013, "forwardPE": -13.227513, "volume": 624067, "regularMarketVolume": 624067, "averageVolume": 884006, "averageVolume10days": 781710, "averageDailyVolume10Day": 781710, "bid": 24.91, "ask": 25.15, "bidSize": 1, "askSize": 1, "marketCap": 2815699968, "fiftyTwoWeekLow": 14.06, "fiftyTwoWeekHigh": 27.29, "priceToSalesTrailing12Months": 43.991188, "fiftyDayAverage": 21.763, "twoHundredDayAverage": 21.22625, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 2076877440, "profitMargins": -2.58905, "floatShares": 54922141, "sharesOutstanding": 112628000, "sharesShort": 7179587, "sharesShortPriorMonth": 6875637, "sharesShortPreviousMonthDate": 1751241600, "dateShortInterest": 1753920000, "sharesPercentSharesOut": 0.0637, "heldPercentInsiders": 0.00385, "heldPercentInstitutions": 1.15703, "shortRatio": 8.6, "shortPercentOfFloat": 0.076, "impliedSharesOutstanding": 112628000, "bookValue": 6.919, "priceToBook": 3.6132388, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -165715008, "trailingEps": -1.59, "forwardEps": -1.89, "enterpriseToRevenue": 32.448, "enterpriseToEbitda": -12.032, "52WeekChange": 0.49164677, "SandP52WeekChange": 0.1513431, "quoteType": "EQUITY", "currentPrice": 25.0, "targetHighPrice": 45.369373, "targetLowPrice": 27.205677, "targetMeanPrice": 40.470535, "targetMedianPrice": 41.31215, "recommendationMean": 1.41667, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 11, "totalCash": 739161984, "totalCashPerShare": 6.563, "ebitda": -172616000, "totalDebt": 328000, "quickRatio": 20.785, "currentRatio": 21.085, "totalRevenue": 64006000, "debtToEquity": 0.042, "revenuePerShare": 0.597, "returnOnAssets": -0.17118, "returnOnEquity": -0.28426, "grossProfits": 64006000, "freeCashflow": -85028000, "operatingCashflow": -124122000, "revenueGrowth": 7.401, "grossMargins": 1.0, "ebitdaMargins": -2.69687, "operatingMargins": -1.86132, "financialCurrency": "USD", "symbol": "NAMS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1755907172, "regularMarketTime": 1755892801, "exchange": "NGM", "messageBoardId": "finmb_685404834", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "cryptoTradeable": false, "shortName": "NewAmsterdam Pharma Company N.V", "longName": "NewAmsterdam Pharma Company N.V.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1612881000000, "postMarketChangePercent": -2.0, "postMarketPrice": 24.5, "postMarketChange": -0.5, "regularMarketChange": 0.559999, "regularMarketDayRange": "24.35 - 25.65", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 884006, "fiftyTwoWeekLowChange": 10.94, "fiftyTwoWeekLowChangePercent": 0.7780938, "fiftyTwoWeekRange": "14.06 - 27.29", "fiftyTwoWeekHighChange": -2.290001, "fiftyTwoWeekHighChangePercent": -0.08391355, "fiftyTwoWeekChangePercent": 49.164677, "earningsTimestamp": 1754539200, "earningsTimestampStart": 1762345800, "earningsTimestampEnd": 1762345800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.59, "epsForward": -1.89, "epsCurrentYear": -1.20564, "priceEpsCurrentYear": -20.735876, "fiftyDayAverageChange": 3.2369995, "fiftyDayAverageChangePercent": 0.14873865, "twoHundredDayAverageChange": 3.7737503, "twoHundredDayAverageChangePercent": 0.17778696, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2022-11-23", "prevName": "Frazier Lifesciences Acquisition Corporation", "nameChangeDate": "2025-08-22", "averageAnalystRating": "1.4 - Strong Buy", "regularMarketChangePercent": 2.29132, "regularMarketPrice": 25.0, "marketState": "CLOSED", "displayName": "NewAmsterdam Pharma Company", "trailingPegRatio": null, "__fetch_time": "2025-08-23"}]